X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
SmithKline tumbles on import duty hurdle - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Apr 28, 2000

    SmithKline tumbles on import duty hurdle

    SmithKline Pharmaceutical has reported disappointing results for the first quarter ended March 2000. While the turnover has declined by 22%, the net profit has actually halved from what was achieved in the corresponding quarter of the last year.

    During last year’s budget the government had imposed a basic import duty of 35% on Engerix (the Hepatitis B vaccine that the company produces). If one takes into account the special additional duty and the surcharge the duty goes up to almost 42.5%. SmithKline was adversely hit since it imports the vaccine from its parent’s Belgian plant.

    The company took a hit on the margins rather than increase the price of the vaccine. This was in view of the competition from the likes of Shanta Biotech (which tied up with Pfizer for marketing) and Wockhardt. Even Hoechst Marion Roussel plans to introduce a Hep–B vaccine in the current year, which would further intensify the competition in this segment.

    Besides, Zevit (B complex vitamin) which contributes around 15% of the turnover was also was also brought under price control during 1999. The company was forced to reduce the prices of the product by almost 50%. This has hit the turnover and the margins further.

    (Rs m) FQFY99 FQFY00 Change
    Sales 879 681 -22.6%
    Other Income 20 24 21.1%
    Expenditure 790 642 -18.8%
    Operating Profit (EBDIT) 89 39 -56.4%
    Operating Profit Margin (%) 10.1% 5.7%  
    Interest 1 0 -67.6%
    Depreciation 5 10 111.8%
    Profit before Tax 103 52 -49.3%
    Other Adjustments      
    Tax 24 13 -44.7%
    Profit after Tax/(Loss) 80 39 -50.7%
    Net profit margin (%) 9.1% 5.8%  
    Earnings per share* 10.83 5.34  
    (annualised)      

    The company has also explained that lower export sales as a result of order phasing as compared to the same quarter of last year also contributed to the de–growth in sales.

    ‘Iodex’ the company flagship over the counter brand also seems to have recorded relatively lower growth in the light of competition from ‘Moov’, ‘Amritanjan’ and ‘Tiger Balm’. However two other vaccines ‘Havrix’ for Hepatitis A and ‘Varilix’ for chicken pox have done reasonably well and are expected to contribute almost 15% of the company’s turnover.

    However the full year impact of the customs duty on Engerix and the price control on Zevit would more than nullify the growth from the two new vaccines. One way out for SmithKline would be to introduce new products from the parent’s stable. Avandia, the parent’s anti–diabetes blockbuster is slated to be introduced in India. However, the vehicle that the parent will use (whether the 100% subsidiary or the listed company) is still open to question.

    The stock currently quotes at Rs 188 at an earnings multiple of 33.7 times. This is more than half the earnings multiple it was quoting at last year.

     

     

    Equitymaster requests your view! Post a comment on "SmithKline tumbles on import duty hurdle". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

    Aug 4, 2017

    The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    TRACK SMITHKLINE PHARMA

    • Track your investment in SMITHKLINE PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    MARKET STATS